Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash & Equivalents (2020 - 2025)

Cytek Biosciences' Cash & Equivalents history spans 6 years, with the latest figure at $90.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 7.97% year-over-year to $90.9 million; the TTM value through Dec 2025 reached $90.9 million, down 7.97%, while the annual FY2025 figure was $90.9 million, 7.97% down from the prior year.
  • Cash & Equivalents reached $90.9 million in Q4 2025 per CTKB's latest filing, down from $93.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $364.6 million in Q4 2021 to a low of $75.5 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $197.4 million, with a median of $163.6 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 132.67% in 2022, then tumbled 62.42% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $364.6 million in 2021, then fell by 18.65% to $296.6 million in 2022, then plummeted by 43.59% to $167.3 million in 2023, then tumbled by 40.99% to $98.7 million in 2024, then decreased by 7.97% to $90.9 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Cash & Equivalents are $90.9 million (Q4 2025), $93.3 million (Q3 2025), and $75.5 million (Q2 2025).